These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14672628)

  • 1. The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation.
    Moreau R
    J Hepatol; 2004 Jan; 40(1):159-61. PubMed ID: 14672628
    [No Abstract]   [Full Text] [Related]  

  • 2. [Influence of circulatory dysfunction on the treatment of ascites and hepatorenal syndrome: vasoconstrictor and diuretic drug treatment].
    Torre A; Terra C; Guevara M; Ginès P
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():8-14. PubMed ID: 15195529
    [No Abstract]   [Full Text] [Related]  

  • 3. [Update on hepatorenal syndrome].
    Blaise P; Moonen M; Rorive G
    Nephrologie; 2002; 23(1):11-7. PubMed ID: 11887572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis.
    Schmidt LE; Ring-Larsen H
    Curr Pharm Des; 2006; 12(35):4637-47. PubMed ID: 17168767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The management of hepatorenal syndrome.
    Carl DE; Sanyal A
    Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.
    Restuccia T; Ortega R; Guevara M; Ginès P; Alessandria C; Ozdogan O; Navasa M; Rimola A; Garcia-Valdecasas JC; Arroyo V; Rodés J
    J Hepatol; 2004 Jan; 40(1):140-6. PubMed ID: 14672625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome.
    Testro AG; Angus PW
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1707-9. PubMed ID: 20136956
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatorenal syndrome: do the vasoconstrictors work?
    Leung W; Wong F
    Gastroenterol Clin North Am; 2011 Sep; 40(3):581-98. PubMed ID: 21893275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of hepatorenal syndrome and liver transplantation.
    Memon I; Klein CL
    Curr Opin Organ Transplant; 2011 Jun; 16(3):301-5. PubMed ID: 21505341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H; Chawla Y
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage.
    Döhler KD; Meyer M
    Best Pract Res Clin Anaesthesiol; 2008 Jun; 22(2):335-50. PubMed ID: 18683479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoconstrictors in hepatorenal syndrome - A critical review.
    Mattos ÂZ; Schacher FC; Mattos AA
    Ann Hepatol; 2019; 18(2):287-290. PubMed ID: 31023616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
    Ganne-Carrié N; Hadengue A; Mathurin P; Durand F; Erlinger S; Benhamou JP
    Dig Dis Sci; 1996 Jun; 41(6):1054-6. PubMed ID: 8654133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.
    Arroyo V; Terra C; Ginès P
    J Hepatol; 2007 May; 46(5):935-46. PubMed ID: 17391801
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatorenal syndrome.
    Bataller R; Arroyo V; Ginès P; Sort P
    Forum (Genova); 1998; 8(1):62-81. PubMed ID: 9565447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatorenal syndrome].
    Lautrette A; Liotier J; Deteix P; Souweine B
    Nephrol Ther; 2009 Apr; 5(2):150-6. PubMed ID: 18514053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation.
    Wong F; Leung W; Al Beshir M; Marquez M; Renner EL
    Liver Transpl; 2015 Mar; 21(3):300-7. PubMed ID: 25422261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?
    Piano S; Morando F; Fasolato S; Cavallin M; Boscato N; Boccagni P; Zanus G; Cillo U; Gatta A; Angeli P
    J Hepatol; 2011 Aug; 55(2):491-6. PubMed ID: 21334405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.
    Saló J; Ginès A; Quer JC; Fernández-Esparrach G; Guevara M; Ginès P; Bataller R; Planas R; Jiménez W; Arroyo V; Rodés J
    J Hepatol; 1996 Dec; 25(6):916-23. PubMed ID: 9007721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of pretransplant treatment of hepatorenal syndrome with terlipressin.
    Solà E; Cárdenas A; Ginès P
    Curr Opin Organ Transplant; 2013 Jun; 18(3):265-70. PubMed ID: 23652609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.